However, the majority of clinical trials involving systemic TNFα treatment were limited by sepsis-like symptoms and showed no efficacy in tumour rejection at the maximally tolerated dose in phase I and phase II trials [117–119]. This evidence concerns the gene TNF and neoplasm.